{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:01:59Z","timestamp":1785546119359,"version":"3.56.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"18","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","award":["1UC1AI062538-01"],"award-info":[{"award-number":["1UC1AI062538-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Joint Science and Technology Office-Chemical, Biological Defense","award":["Plan1.1C0041_09_RD_B"],"award-info":[{"award-number":["Plan1.1C0041_09_RD_B"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.vaccine.2010.02.056","type":"journal-article","created":{"date-parts":[[2010,3,2]],"date-time":"2010-03-02T09:49:17Z","timestamp":1267523357000},"page":"3143-3151","source":"Crossref","is-referenced-by-count":31,"title":["Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus"],"prefix":"10.1016","volume":"28","author":[{"given":"Shannon S.","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell R.","family":"Bakken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathleen M.","family":"Lind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Kate","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald L.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2010.02.056_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1146\/annurev.me.25.020174.000301","article-title":"Venezuelan equine encephalitis virus infection in man","volume":"25","author":"Ehrenkranz","year":"1974","journal-title":"Annu Rev Med"},{"issue":"2","key":"10.1016\/j.vaccine.2010.02.056_bib2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/oxfordjournals.aje.a121233","article-title":"Venezuelan equine encephalomyelitis: surveys of human illness during an epizootic in Guatemala and El Salvador","volume":"93","author":"Hinman","year":"1971","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.vaccine.2010.02.056_bib3","first-page":"150","article-title":"Venezulean equine encephalomyelitis; laboratory aspects of fourteen human cases following vaccination and attempts to isolate the virus from the vaccine","volume":"63","author":"Smith","year":"1956","journal-title":"Am J Hyg"},{"key":"10.1016\/j.vaccine.2010.02.056_bib4","unstructured":"Kortepeter M, Christopher G, Cieslak T, Culpepper R, Darling R. USAMRIID's Medical Management of Biological Casualities Handbook. 4th ed. Fort Detrick, MD: 2001."},{"issue":"4","key":"10.1016\/j.vaccine.2010.02.056_bib5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4269\/ajtmh.1963.12.597","article-title":"Use of an attenuated strain of venezuelan equine encephalomyelitis virus for immunization in man","volume":"12","author":"McKinney","year":"1963","journal-title":"Am J Trop Med Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2010.02.056_bib6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/AEM.27.1.150-153.1974","article-title":"Inactivated Venezuelan equine encephalomyelitis vaccine prepared from attenuated (TC-83 strain) virus","volume":"27","author":"Cole","year":"1974","journal-title":"Appl Microbiol"},{"issue":"3","key":"10.1016\/j.vaccine.2010.02.056_bib7","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/136.3.354","article-title":"Persistence in humans of antibody to subtypes of Venezuelan equine encephalomyelitis (VEE) virus after immunization with attenuated (TC- 83) VEE virus vaccine","volume":"136","author":"Burke","year":"1977","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2010.02.056_bib8","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0264-410X(95)00168-Z","article-title":"Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine","volume":"14","author":"Pittman","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.02.056_bib9","series-title":"Proc. of the Workshop Symposium on Venezuelan Encephalitis","first-page":"369","article-title":"Inactivated and live VEE vaccines\u2014a review","author":"McKinney","year":"1972"},{"issue":"5","key":"10.1016\/j.vaccine.2010.02.056_bib10","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/infdis\/140.5.708","article-title":"Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C-84)","volume":"140","author":"Edelman","year":"1979","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2010.02.056_bib11","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1006\/viro.1995.1458","article-title":"Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1","volume":"212","author":"Davis","year":"1995","journal-title":"Virology"},{"issue":"10","key":"10.1016\/j.vaccine.2010.02.056_bib12","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.vaccine.2006.10.030","article-title":"Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses","volume":"25","author":"Fine","year":"2007","journal-title":"Vaccine"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2010.02.056_bib13","first-page":"616","article-title":"Onset and duration of protective immunity to IA\/IB and IE strains of Venezuelan equine encephalitis virus in vaccinated mice","volume":"20","author":"Hart","year":"2002","journal-title":"Vaccine"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2010.02.056_bib14","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1016\/S0264-410X(03)00328-1","article-title":"Genetically engineered, live attenuated vaccines for Venezuelan equine encephalitis: testing in animal models","volume":"21","author":"Pratt","year":"2003","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2010.02.056_bib15","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1086\/444397","article-title":"Aerosol exposure to western equine encephalitis virus causes fever and encephalitis in cynomolgus macaques","volume":"192","author":"Reed","year":"2005","journal-title":"J Infect Dis"},{"issue":"49","key":"10.1016\/j.vaccine.2010.02.056_bib16","doi-asserted-by":"crossref","first-page":"6814","DOI":"10.1016\/j.vaccine.2009.09.013","article-title":"Telemetric analysis to detect febrile responses in mice following vaccination with a live-attenuated virus vaccine","volume":"27","author":"Martin","year":"2009","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2010.02.056_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.biologicals.2006.02.008","article-title":"Developments in the production and quality control of poliovirus vaccines -- historical perspectives","volume":"34","author":"Furesz","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2010.02.056_bib18","unstructured":"Japanese Encephalitis Virus Vaccine, Inactivated, Adsorbed Approval Letter, http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm142577.htm. 2009."},{"key":"10.1016\/j.vaccine.2010.02.056_bib19","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jviromet.2009.11.006","article-title":"A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV)","volume":"163","author":"Fine","year":"2009","journal-title":"J Virol Methods"},{"issue":"7","key":"10.1016\/j.vaccine.2010.02.056_bib20","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1002\/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U","article-title":"Identification of CpG oligonucleotide sequences with high induction of IFN-alpha\/beta in plasmacytoid dendritic cells","volume":"31","author":"Krug","year":"2001","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2010.02.056_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/dna.2005.24.63","article-title":"Superior activity of the type C class of ISS in vitro and in vivo across multiple species","volume":"24","author":"Marshall","year":"2005","journal-title":"DNA Cell Biol"},{"issue":"14","key":"10.1016\/j.vaccine.2010.02.056_bib22","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/0264-410X(95)00011-O","article-title":"Adjuvants for human vaccines\u2014current status, problems and future prospects","volume":"13","author":"Gupta","year":"1995","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2010.02.056_bib23","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.vaccine.2006.07.056","article-title":"Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109","volume":"25","author":"Gu","year":"2007","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2010.02.056_bib24","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.intimp.2006.03.009","article-title":"The efficacy of CpG oligodinucleotides, in combination with conventional adjuvants, as immunological adjuvants to swine streptococcic septicemia vaccine in piglets in vivo","volume":"6","author":"Linghua","year":"2006","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2010.02.056_bib25","unstructured":"FDA Guidance. Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Vaccine or Related Product. U.S. Dept. Health and Human Services, Food and Drug Administration, Center for Biological Evaluation and Research. 1999."},{"key":"10.1016\/j.vaccine.2010.02.056_bib26","unstructured":"Beaty BJ, Calisher CH, Shope RE, Schmidt NJ, Emmons RW, editors. Diagnostic procedures for viral, rickettsial and chlamydial infections. 6th ed. Washington, DC: American Public Health Association; 1989; Arboviruses. p. 797\u2013855."},{"issue":"2","key":"10.1016\/j.vaccine.2010.02.056_bib27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0042-6822(85)90343-5","article-title":"The neutralization site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes","volume":"142","author":"Roehrig","year":"1985","journal-title":"Virology"},{"issue":"9\u201310","key":"10.1016\/j.vaccine.2010.02.056_bib28","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/S0264-410X(97)00192-8","article-title":"Use of telemetry to assess vaccine-induced protection against parenteral and aerosol infections of Venezuelan equine encephalitis virus in non-human primates","volume":"16","author":"Pratt","year":"1998","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2010.02.056_bib29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jmv.1890380414","article-title":"Venezuelan equine encephalitis-specific immunoglobulin responses: live attenuated TC-83 versus inactivated C-84 vaccine","volume":"38","author":"Engler","year":"1992","journal-title":"J Med Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2010.02.056_bib30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1006\/viro.1997.8878","article-title":"Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo","volume":"239","author":"Pushko","year":"1997","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2010.02.056_bib31","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1152\/ajplegacy.1947.150.1.70","article-title":"Measurement of the respiratory volumes oflaboratory animals","volume":"150","author":"Guyton","year":"1947","journal-title":"Am J Physiol"},{"issue":"3","key":"10.1016\/j.vaccine.2010.02.056_bib32","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3181\/00379727-125-32194","article-title":"A plaque neutralization method for arboviruses","volume":"125","author":"Earley","year":"1967","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.vaccine.2010.02.056_bib33","unstructured":"Food and Drug Administration. Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals. Food and Drug Administration, Center for Biologics Evaluation and Research, Rockville, MD. 1993."},{"issue":"43","key":"10.1016\/j.vaccine.2010.02.056_bib34","doi-asserted-by":"crossref","first-page":"7573","DOI":"10.1016\/j.vaccine.2007.07.061","article-title":"Chimeric Sindbis\/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice","volume":"25","author":"Wang","year":"2007","journal-title":"Vaccine"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2010.02.056_bib35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4269\/ajtmh.2001.64.49","article-title":"Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice","volume":"64","author":"Ludwig","year":"2001","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"10.1016\/j.vaccine.2010.02.056_bib36","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1128\/JCM.19.3.429-431.1984","article-title":"Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters","volume":"19","author":"Jahrling","year":"1984","journal-title":"J Clin Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2010.02.056_bib37","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0264-410X(96)00204-6","article-title":"Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB\/c, but not C3H\/HeN mice","volume":"15","author":"Hart","year":"1997","journal-title":"Vaccine"},{"issue":"7\u20138","key":"10.1016\/j.vaccine.2010.02.056_bib38","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0264-410X(98)00315-6","article-title":"TC-83 vaccine protects against airborne or subcutaneous challenge with heterologous mouse-virulent strains of Venezuelan equine encephalitis virus","volume":"17","author":"Phillpotts","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.02.056_bib39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-065X.1997.tb01013.x","article-title":"The role of antibody in recovery from alphavirus encephalitis","volume":"159","author":"Griffin","year":"1997","journal-title":"Immunol Rev"},{"issue":"3","key":"10.1016\/j.vaccine.2010.02.056_bib40","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1128\/JVI.55.3.594-600.1985","article-title":"Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies","volume":"55","author":"Mathews","year":"1985","journal-title":"J Virol"},{"issue":"2","key":"10.1016\/j.vaccine.2010.02.056_bib41","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.virol.2007.05.041","article-title":"Alpha-beta T cells provide protection against lethal encephalitis in the murine model of VEEV infection","volume":"367","author":"Paessler","year":"2007","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.vaccine.2010.02.056_bib42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4269\/ajtmh.2008.78.83","article-title":"Protection of mice by equine herpesvirus type 1 based experimental vaccine against lethal Venezuelan equine encephalitis virus infection in the absence of neutralizing antibodies","volume":"78","author":"Rosas","year":"2008","journal-title":"Am J Trop Med Hyg"},{"issue":"2\u20133","key":"10.1016\/j.vaccine.2010.02.056_bib43","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0264-410X(00)00123-7","article-title":"An immunological profile of Balb\/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine","volume":"19","author":"Bennett","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2010.02.056_bib44","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.vaccine.2009.10.126","article-title":"Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB","volume":"28","author":"Martin","year":"2010","journal-title":"Vaccine"},{"issue":"26","key":"10.1016\/j.vaccine.2010.02.056_bib45","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1016\/S0264-410X(00)00042-6","article-title":"Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate","volume":"18","author":"Hart","year":"2000","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2010.02.056_bib46","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.4049\/jimmunol.181.6.4188","article-title":"Trafficking of antigen-specific CD8+ T lymphocytes to mucosal surfaces following intramuscular vaccination","volume":"181","author":"Kaufman","year":"2008","journal-title":"J Immunol"},{"issue":"51","key":"10.1016\/j.vaccine.2010.02.056_bib47","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.1016\/j.vaccine.2008.09.057","article-title":"Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model","volume":"26","author":"Hagenaars","year":"2008","journal-title":"Vaccine"},{"issue":"13","key":"10.1016\/j.vaccine.2010.02.056_bib48","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/S0264-410X(98)00008-5","article-title":"Induction of protective immune responses against Venezuelan equine encephalitis (VEE) virus aerosol challenge with microencapsulated VEE virus vaccine","volume":"16","author":"Greenway","year":"1998","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2010.02.056_bib49","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/vim.2008.0052","article-title":"CpG used as an adjuvant for an adenovirus-based Venezuelan equine encephalitis virus vaccine increases the immune response to the vector, but not to the transgene product","volume":"21","author":"Perkins","year":"2008","journal-title":"Viral Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2010.02.056_bib50","first-page":"395","article-title":"The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer","volume":"1","author":"Kass-Eisler","year":"1994","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2010.02.056_bib51","first-page":"209","article-title":"Attenuation of Venezuelan Equine Encephalomyelitis virus by In Vitro cultivation in guinea-pig heart cells","volume":"73","author":"Berge","year":"1961","journal-title":"Am J Hyg"},{"issue":"6","key":"10.1016\/j.vaccine.2010.02.056_bib52","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1128\/IAI.7.6.905-910.1973","article-title":"Homegeneity of Venezuelan encephalitis virion populations of hamster-virulent and benign strains, including the attenuated TC83 vaccine","volume":"7","author":"Jahrling","year":"1973","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10002379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X10002379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T19:23:19Z","timestamp":1590693799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X10002379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":52,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0264410X10002379"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2010.02.056","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}